Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 3,623 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NIDDM Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

NCT06112418
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Interventions
The Cleerly CAD Staging System
Device
Lead sponsor
Cleerly, Inc.
Industry
Eligibility
55 Years and older
Enrollment
7,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
125
States / cities
Chandler, Arizona • Scottsdale, Arizona • Sun City, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Not applicable Interventional

Mechanisms of Diabetes Relapse After Bariatric Surgery

NCT01516320
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Roux-en-Y Gastric Bypass, Laparoscopic adjustable gastric banding, Vertical Sleeve Gastrectomy
Procedure
Lead sponsor
Blandine Laferrere
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 29, 2026, 4:43 PM EDT
Recruiting Not applicable Interventional

ED Diabetes Screening and Outpatient Care - Aim 3

NCT05899023
View directory record Official record
Conditions
Diabetes Mellitus, Non Insulin Dependent Diabetes Mellitus
Interventions
Telehealth Bridge Visits, Standard of Care
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
20 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Not applicable Interventional

Lifestyle Modification Program to Reduce Risk of Coronary Heart Disease in Latina Women With Diabetes

NCT00233259
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Diabetes Mellitus, Type 2
Interventions
Mediterranean Diet, Physical Activity, Stress Management, Social Support, Smoking Cessation, Control group
Behavioral · Other
Lead sponsor
Oregon Research Institute
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 25, 2011 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 1 Interventional

To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

NCT01176097
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD5658, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 29, 2026, 4:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diabetes Effects on Long-Term Implant Survival and Success

NCT02282046
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
25 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Not applicable Interventional

Pilot Study of the Effects of Erythritol on Endothelial Function in Patients With Type 2 Diabetes Mellitus

NCT01609088
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Erythritol-containing beverage
Dietary Supplement
Lead sponsor
Boston University
Other
Eligibility
35 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Oct 29, 2026, 4:43 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.

NCT07106879
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Syndrome, Obesity, Prediabetes, Mental Health Disorders, Endocrine Dysfunction, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD)
Interventions
Blood Work
Other
Lead sponsor
Clindove Research LLC
Other
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 29, 2026, 4:43 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

NCT00998686
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
dutogliptin, sitagliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Montgomery, Alabama • Tempe, Arizona • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe

NCT01524770
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulaglutide
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Oct 29, 2026, 4:43 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06660173
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Maridebart Cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Anaheim, California • Canoga Park, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

NCT05872620
View directory record Official record
Conditions
Obesity, Overweight, Type 2 Diabetes
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Pelham, Alabama • Tucson, Arizona • Yuma, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 4 Interventional

Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics

NCT01654120
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Liraglutide, Insulin
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Whole Grains, Gastric Emptying and Glycemic Response

NCT03467659
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2, Appetitive Behavior
Interventions
Cracked whole wheat porridge, Semolina wheat porridge, Whole wheat flour porridge, Refined wheat flour porridge, Refined wheat flour porridge,fine bran, Refined wheat flour porridge,coarse bran
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects

NCT00625859
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK189075, Bupropion, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 29, 2026, 4:43 PM EDT
Recruiting Not applicable Interventional

Diabetes Body Project 2

NCT07468188
View directory record Official record
Conditions
Eating Disorders, Type 2 Diabetes
Interventions
Body Project Type 2
Behavioral
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 29, 2026, 4:43 PM EDT
Withdrawn Phase 3 Interventional

Pioglitazone and Insulin Resistance in ADT

NCT05098327
View directory record Official record
Conditions
Prostate Cancer, Insulin Resistance, Diabetes Mellitus, Type 2, Androgen Deficiency
Interventions
Pioglitazone 30 mg, Placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 29, 2026, 4:43 PM EDT
Recruiting Not applicable Interventional

A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabetes Mellitus (RESTORE-1 Study)

NCT07355270
View directory record Official record
Conditions
Type-2 Diabetes Mellitus
Interventions
RF Vapor Ablation
Device
Lead sponsor
Aqua Medical, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Scottsdale, Arizona • Newport Beach, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

NCT04029480
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ertugliflozin 5 mg, Ertugliflozin 15 mg, Placebo to ertugliflozin 15 mg, Placebo to ertugliflozin 5 mg, Insulin, Metformin
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
10 Years to 17 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 29, 2026, 4:43 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Effects of a Red/Gold/IR LED Combination Light on Reduction of Fat

NCT04525573
View directory record Official record
Conditions
Body Image, Diabetes Mellitus, Type 2
Interventions
LLLT Combination Red/Gold/IR Therapy
Device
Lead sponsor
Ward Photonics LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Schaumburg, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

NCT01164501
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
BI 10773, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Anaheim, California • Lomita, California • Plantation, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 2 Interventional

Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

NCT03604419
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
PB-119 100 μg+ Glucophage®, PB-119 150 μg+ Glucophage®, PB-119 200 μg+ Glucophage®, PB-119 placebo + Glucophage®
Drug
Lead sponsor
PegBio Co., Ltd.
Other
Eligibility
18 Years to 70 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 2 Interventional

Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

NCT05570305
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan
Drug
Lead sponsor
University Medical Center Groningen
Other
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 2 Interventional

A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

NCT01607294
View directory record Official record
Conditions
Hyperlipidemia, Type 2 Diabetes
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 29, 2026, 4:43 PM EDT